Regresa al Registro Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorBekaii-Saab, Tanios S
dc.contributor.authorOkusaka, Takuji
dc.contributor.authorGoldstein, David
dc.contributor.authorUeno, Makoto
dc.contributor.authorIoka, Tatsuya
dc.contributor.authorTabernero Caturla, Josep
dc.contributor.authorOh, Do-Youn
dc.date.accessioned2023-04-04T06:25:32Z
dc.date.available2023-04-04T06:25:32Z
dc.date.issued2023-04
dc.identifier.citationBekaii-Saab T, Okusaka T, Goldstein D, Oh DY, Ueno M, Ioka T, et al. Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial. eClinicalMedicine. 2023 Apr;58:101897.
dc.identifier.issn2589-5370
dc.identifier.urihttps://hdl.handle.net/11351/9288
dc.descriptionAdenocarcinoma; Napabucasin; Cáncer de páncreas
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofserieseClinicalMedicine;58
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subjectPàncrees - Càncer - Tractament
dc.subjectMedicaments antineoplàstics - Ús terapèutic
dc.subject.meshPancreatic Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.mesh/therapeutic use
dc.subject.meshTreatment Outcome
dc.titleNapabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.eclinm.2023.101897
dc.subject.decsneoplasias pancreáticas
dc.subject.decs/farmacoterapia
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada
dc.subject.decs/uso terapéutico
dc.subject.decsresultado del tratamiento
dc.relation.publishversionhttps://doi.org/10.1016/j.eclinm.2023.101897
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Bekaii-Saab T] Division of Hematology and Medical Oncology, Mayo Clinic Arizona, Scottsdale, AZ, USA. [Okusaka T] Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan. [Goldstein D] Department of Medical Oncology, Prince of Wales Hospital, Randwick, NSW, Australia. [Oh DY] Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Republic of Korea. [Ueno M] Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Kanagawa, Japan. [Ioka T] Oncology Center, Yamaguchi University Hospital, Yamaguchi, Japan. [Tabernero J] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, Barcelona, Spain
dc.identifier.pmid36969338
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Ficheros en el ítem

Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Regresa al Registro Simple